No Data
No Data
Why We're Not Concerned Yet About Lepu Biopharma Co., Ltd.'s (HKG:2157) 26% Share Price Plunge
Lepu Biopharma Co., Ltd. (HKG:2157) shares have retraced a considerable 26% in the last month, reversing a fair amount of their solid recent performance. Instead of being rewarded, shareholders who
Changes in Hong Kong stocks | Lepu Bio-B (02157) is now up more than 8%. The company has released a number of research results and recently raised funds for ADC candidate product development
Lepu Bio-B (02157) is now up more than 8%. As of press release, it has risen 7.83% to HK$4.82, with a turnover of HK$28.239,500.
Lepu Bio-B (02157.HK) successfully placed 51.17 million shares to raise HK$230 million
On May 24, GLONGHUI | Lepu Bio-B (02157.HK) announced that all conditions of the placement matters contained in the placement agreement (including (including) approval by the Listing Committee for the listing and trading of the placement shares) have been met, and that the placement was completed on May 24, 2024. The company has successfully placed a total of 51.17 million shares at the placement price of HK$4.58 per share to no less than six undertakers, accounting for about 3.09% and 2.99% of all issued H shares and all issued shares after the expansion of the allotted shares issued and issued, respectively. Total proceeds from placement transactions and proceeds
Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7%
Lepu Biopharma (HKG:2157) will present three clinical studies during a meeting of the American Society of Clinical Oncology, according to a Friday filing with the Hong Kong Stock Exchange. The biophar
Changes in Hong Kong stocks | Lepu Bio-B (02157) fell more than 12% from the monthly high point and already fell 35% to raise HK$230 million in the proposed discounted placement of shares
Lepu Bio-B (02157) fell more than 12% in the intraday period, to a low of HK$4.23. It is already 35% lower than the monthly high of HK$6.5. As of press release, it decreased by 7.52% to HK$4.55, with a turnover of HK$357.44,300.
Lepu Bio-B (02157.HK): Results of three clinical studies were announced at the 2024 ASCO Annual Meeting
On May 24, GLONGHUI (02157.HK) announced the results of three clinical studies of the company's innovative drug candidates and combination therapies (including antibody drug conjugates (“ADC”) MRG004A, MRG003 and HX008, and combination therapy with HX008 and Nirapali at the 2024 American Society of Clinical Oncology (“ASCO”) annual meeting.
No Data